PI3K inhibitors in haematological malignancies
- PMID: 35901824
- DOI: 10.1016/S1470-2045(22)00260-1
PI3K inhibitors in haematological malignancies
Conflict of interest statement
VP declares research funding from Arnold Ventures; royalties from Johns Hopkins Press, Medscape, and MedPage; consulting for UnitedHealthcare; speaking fees from Evicore and New Century Health; and that his plenary session podcast is supported by Patreon subscriptions. DJB declares no competing interests.
Comment on
-
The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint.Lancet Oncol. 2022 May;23(5):563-566. doi: 10.1016/S1470-2045(22)00200-5. Epub 2022 Apr 14. Lancet Oncol. 2022. PMID: 35429996 No abstract available.

